Athena Heart 310 Apr 2026

Targeted protein levels decreased by an average of 73%.

(often associated with ATHENA trial contexts in heart disease research) is an experimental in vivo CRISPR gene-editing therapy designed to provide a one-time treatment for cardiovascular disease risk factors. It specifically targets the ANGPTL3 gene in the liver to permanently lower high levels of triglycerides (TG) and "bad" LDL cholesterol. 💡 Key Trial Results (Phase 1) ATHENA HEART 310

ANGPTL3 is a protein that normally inhibits enzymes that clear lipids from the blood. By "turning off" this gene, the body can more effectively remove fats. Targeted protein levels decreased by an average of 73%

Unlike daily pills or bi-monthly injections, CTX310 aims for a durable, permanent solution by editing DNA directly: 💡 Key Trial Results (Phase 1) ANGPTL3 is

Average drops of ~55% at the highest dose, with some patients seeing up to 84% reduction .

The therapy is being tested for those with severe hypertriglyceridemia (sHTG), mixed dyslipidemia, and familial hypercholesterolemia (HoFH/HeFH). 🚀 Future Outlook